Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REVB

Revelation Biosciences Inc

Sep 12 • 04:00PM ET

1.92

-0.08 -4.00 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NVAX AXSM BCRX AVIR CYTK REPL OCUL PGEN IMUX

Index	-	P/E	-	EPS (ttm)	-68.43	Insider Own	0.00%	Shs Outstand	1.70M	Perf Week	-33.10%
Market Cap	3.26M	Forward P/E	-	EPS next Y	-7.25	Insider Trans	-	Shs Float	1.70M	Perf Month	-23.81%
Enterprise Value	-1.91M	PEG	-	EPS next Q	-1.59	Inst Own	2.25%	Short Float	13.52%	Perf Quarter	-20.50%
Income	-11.64M	P/S	-	EPS this Y	95.46%	Inst Trans	138.91%	Short Ratio	0.57	Perf Half Y	-80.43%
Sales	0.00M	P/B	0.77	EPS next Y	39.25%	ROA	-95.82%	Short Interest	0.23M	Perf YTD	-91.32%
Book/sh	2.49	P/C	0.63	EPS next 5Y	72.82%	ROE	-340.81%	52W High	60.48 -96.83%	Perf Year	-95.30%
Cash/sh	3.04	P/FCF	-	EPS past 3/5Y	83.74% -	ROIC	-304.37%	52W Low	1.96 -2.04%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.55% 8.36%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	94.99%	Oper. Margin	-	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	30.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.42	EPS Q/Q	97.15%	SMA20	-26.68%	Beta	-0.05	Target Price	21.25
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-27.61%	Rel Volume	0.62	Prev Close	2.00
Employees	9	LT Debt/Eq	0.00	Earnings	Aug 08 BMO	SMA200	-80.60%	Avg Volume	405.62K	Price	1.92
IPO	Nov 17, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-153.99% -	Trades		Volume	250,800	Change	-4.00%

Sep-11-25 08:30AM	Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds (ACCESSWIRE) -19.03%
Sep-10-25 07:20AM	Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data (ACCESSWIRE) +6.01%
Sep-09-25 08:00AM	Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study (ACCESSWIRE) -17.38%
Aug-08-25 06:30AM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 (Business Wire) -6.67%
Jul-24-25 09:00AM	Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research (Business Wire)
09:00AM	Loading…
Jul-16-25 09:00AM	Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study (Business Wire)
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jul-01-25 05:26PM	Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 (Business Wire) +9.33% -6.09%
May-29-25 10:56PM	Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering (Insider Monkey) -54.40%
04:05PM	Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering (Business Wire)
08:00AM	Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering (Business Wire)
May-23-25 04:05PM	Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors (Business Wire) -6.18% -6.58%
May-08-25 04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 (Business Wire) +6.92%
Apr-29-25 09:00AM	Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients (Business Wire)
Apr-10-25 09:23AM	Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? (Insider Monkey) -5.94%
06:00AM	Loading…
Mar-17-25 06:00AM	Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells (Business Wire) -11.76%
Mar-13-25 06:00AM	Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference (Business Wire)
Mar-06-25 04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 (Business Wire)
Feb-26-25 06:00AM	Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients (Business Wire)
Feb-24-25 06:00AM	Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval (Business Wire)
Jan-24-25 06:00AM	Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 (Business Wire) -23.84%
Jan-21-25 06:00AM	Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients (Business Wire)
Jan-13-25 06:00AM	Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 (Business Wire) -5.47%
Jan-06-25 06:00AM	Nasdaq Grants Revelation Biosciences Inc. Continued Listing (Business Wire)
Dec-03-24 08:38AM	Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds (Business Wire) -46.84%
Dec-02-24 06:00AM	Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND (Business Wire) +24.99%
Nov-12-24 06:00AM	Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply (Business Wire) -6.49%
Nov-08-24 04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 (Business Wire) +26.83%
Sep-24-24 06:00AM	Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 (Business Wire)
Aug-21-24 05:30PM	Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds (Business Wire) +101.27% -40.19%
09:53PM	Loading…
Aug-09-24 09:53PM	REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024 (InvestorPlace) -7.68%
04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 (Business Wire)
Jun-24-24 09:00AM	Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity (Business Wire) +13.74%
Jun-13-24 09:21AM	Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini (Business Wire)
May-10-24 09:53PM	REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024 (InvestorPlace) -6.36% -10.68%
04:52PM	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 (Business Wire)
Mar-22-24 09:52PM	REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:15PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 (Business Wire)
Mar-13-24 09:00AM	Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) -16.67%
Mar-12-24 09:00AM	Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference (Business Wire) -7.14%
Mar-04-24 09:00AM	Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini (Business Wire) -6.32%
Feb-13-24 09:00AM	Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) +8.70%
Feb-05-24 04:41PM	Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering (Business Wire) +5.09% -18.75%
Feb-01-24 08:27AM	Why Is Revelation Biosciences (REVB) Stock Down 62% Today? (InvestorPlace) -63.86%
06:00AM	Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering (Business Wire)
Jan-30-24 09:00AM	Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) (Business Wire) -38.80%
Jan-29-24 08:26AM	Why Is Revelation Biosciences (REVB) Stock Up 61% Today? (InvestorPlace) +31.66%
Jan-23-24 09:00AM	Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 (Business Wire) -21.38%
Nov-13-23 04:05PM	Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 (Business Wire) +7.89%
Oct-12-23 09:00AM	Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies (Business Wire)
Oct-04-23 09:00AM	Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference (Business Wire)
Oct-02-23 09:00AM	Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors (Business Wire)
Aug-14-23 07:36AM	REVB Reports Solid Balance Sheet and Remains on Track (Zacks)
Aug-11-23 04:10PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 (Business Wire)
Jun-29-23 09:00AM	REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders (Business Wire)
Jun-22-23 10:24AM	REVB: REVB Looks Attractive Ahead of Trials (Zacks Small Cap Research)
Jun-12-23 04:15PM	Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal (Business Wire)
May-22-23 09:00AM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress (Business Wire) +7.21%
Mar-30-23 05:42PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress (Business Wire)
Mar-13-23 09:00AM	Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board (Business Wire)
Mar-06-23 09:00AM	Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference (Business Wire)
Feb-13-23 04:20PM	Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering (Business Wire) -5.59%
Feb-09-23 09:42AM	Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering (Business Wire) -48.51%
Feb-07-23 09:00AM	Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 (Business Wire) -22.65%
Jan-31-23 12:00PM	Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders (Business Wire) +5.26%
Jan-10-23 09:00AM	Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 (Business Wire)
Nov-18-22 09:00AM	Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model (Business Wire)
Nov-10-22 04:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress (Business Wire) +7.79%
Oct-25-22 11:13AM	Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease (Business Wire) +64.60%
Oct-06-22 07:00AM	Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement (Business Wire) +14.44%
Aug-15-22 05:30PM	Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress (GlobeNewswire) -5.76%
Jul-29-22 11:45AM	Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering (GlobeNewswire) -6.10%
Jul-26-22 08:15AM	Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering (GlobeNewswire) -51.39%
Jul-22-22 06:30PM	Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -23.04% +55.38%
Jul-14-22 09:00AM	Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) +16.10%
Jun-13-22 09:00AM	Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire) -12.73%
May-23-22 09:00AM	Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis (GlobeNewswire)
May-16-22 04:01PM	Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress (GlobeNewswire)
Apr-06-22 09:00AM	Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update (GlobeNewswire)
Mar-30-22 09:00AM	Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -38.32%
Mar-24-22 09:00AM	Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +11.94%
Mar-22-22 09:00AM	Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC (GlobeNewswire) +6.54%
Mar-15-22 09:00AM	Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) +22.55%
Mar-08-22 09:00AM	Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference (GlobeNewswire)
Feb-07-22 09:00AM	Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference (GlobeNewswire) +9.58%
Jan-24-22 08:00AM	Revelation Biosciences Raises $7.76 Million in Equity Financing (GlobeNewswire) -19.15%
Jan-20-22 09:00AM	Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection (GlobeNewswire) -18.50%
Jan-18-22 09:00AM	Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis (GlobeNewswire) -27.25%
Jan-13-22 01:54PM	REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company (GlobeNewswire) -19.03%
Jan-01-01 12:00AM	Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering (Insider Monkey)

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REVB

Revelation Biosciences Inc

Upgrade your FINVIZ experience